Peptide fractions promoting growth and synthesis of desired product(s) into cell and/or tissue culture

ABSTRACT

The invention relates to preparing and/or supplementing a cell or tissue culture medium. In particular, said invention relates to a serum-free and/or protein-free cell culture medium comprising peptide fractions isolated from rapseeds, in particular rapseeds cakes. A method for the production of a cell culture comprising said peptide fractions and for the use thereof is also disclosed.

The present application is a 37 C.F.R. §1.53(b) divisional of, andclaims priority to, U.S. application Ser. No. 11/792,953, filed Aug. 29,2007. Application Ser. No. 11/792,953 is the national phase under U.S.C.§371 of International Application No. PCT/EP2005/056782, filed on Dec.14, 2005. Priority is also claimed to French Application No. 0413250filed on Dec. 14, 2004. The entire contents of each of theseapplications is hereby incorporated by reference.

The present invention relates to the field of supplementing of cell ortissue culture media. More particularly, the present invention relatesto a serum-free and/or protein-free cell culture medium comprisingpeptide fractions isolated from rapeseeds, in particular rapeseed cakes.The invention also relates to a method of cell culture comprising thesepeptide fractions and also to the use thereof.

Since the existence of live cells became known, cell culture types andtechniques have not ceased to increase and to diversify.

Initially, cell cultures used undefined media such as plasma, serum orembryonic extracts. It wasn't until the mid-1950s that the first definedculture medium emerged, said medium comprising, in addition to salts andglucose, various amino acids and vitamins that the cells could notsynthesize.

More recently, it has been shown that, among all the amino acidsprovided, L-glutamine plays an essential role both as a source of energyand as a source of carbon and nitrogen, mainly for allowing purine andpyrimidine synthesis. However, a first drawback lies in the fact thatglutamine is not stable in free amino acid form and will have a tendencyto decompose to ammonium ions and pyroglutamic acid. A solution to thisproblem, based on the use of cereal hydrolyzates, has been provided bypatent application WO 96/26266 filed in the name of QUEST INTERNATIONAL.

In general, cells and tissues, and more particularly animal cells, arecultured in vitro in a nutritional medium, called base or basal medium,supplemented with 5 to 20% of serum, generally fetal calf serum or FCS.

However, the use of such sera has other drawbacks, such as i) theintroduction of animal proteins that must subsequently be eliminated,ii) the potential introduction of contaminants such as fungi, bacteria,viruses or prions, and iii) a variable quality and high costs.

In addition, in order to limit more particularly the risks of bovinespongiform encephalopathy (BSE) in pharmaceutical products, bothnational legislation and international legislation anticipate that theuse of products of animal origin will be prohibited in the near future.

Among these drawbacks, the risk of introducing contaminants remains themost problematic and has prompted the use of serum-free medium or SFM.However, certain SFMs used today still contain peptones and hydrolyzatesderived from animals and are not therefore entirely satisfactory interms of the contamination risks defined above.

As regards SFMs devoid of material of animal origin, they are generallyderived from protein-rich starting materials such as, for example,cereal starting materials, for instance rice (WO 98/15614; WO 99/57246)or wheat. By way of example of other starting materials used, mentionmay also be made of soybean (WO 01/23527; WO 00/03000), or else cucumber(WO 99/47648). However, such culture media are relatively costly toobtain and are generally derived from starting materials with a highprotein potential that can be used for other applications such as, forexample, food applications.

There exists therefore a real need to develop culture media that arecompletely devoid of animal-derived products and inexpensive or, at thevery least, derived from a starting material whose value is and/or canbe only slightly exploited.

The present invention proposes to overcome this shortcoming of the priorart by proposing a culture medium devoid of serum and obtained from aplant starting material with a low initial protein content.

More particularly, the present invention relates to the use of a peptideextract for preparing and/or supplementing a serum-free in vitro cell ortissue culture medium, said extract being obtained by successivefractionations of a plant starting material, characterized in that saidplant starting material consists of rapeseed.

The term “serum-free medium” should be understood to mean a mediumdevoid of serum of animal origin, such as FCS, FBS (fetal bovine serum)or any analogous serum.

Today, most products derived from cell culture are monoclonalantibodies, viruses and recombinant proteins. From an industrial pointof view, the cells most widely cultured today, besides cells fromtissues or as a replacement for animal models in toxicology, arehybridomas, VERO cells (African green monkey kidney cells), BHK cells(baby hamster kidney), CHO cells (Chinese hamster ovary), NSO cells, orSpodoptera frugiperda (Sf9) cells infected with a baculovirus.Hybridomas are monoclonal antibody-producing cells, whereas VERO and CHOcells are generally used for the production of viruses or else ofrecombinant proteins. Of course, this listing is in no way limiting andthe present invention may relate to cells of any type.

By way of nonlimiting examples, mention may also be made of thefollowing tissues: cartilage, muscle cells, skin, bone cells, tendons,embryonic cells, artificial organs.

A first characteristic of the invention is based on the very use ofoil-yielding plants, and most particularly of rapeseed. In fact, unlikethe cereals or other starting materials used to date, this seed isparticularly rich in lipids and low in proteins. For these reasons,those skilled in the art have not, to date, sought to use rapeseed forthe preparation of culture media since it was accepted that, for thispurpose, it was necessary to preferentially use protein-rich startingmaterials.

Entirely surprisingly, and contrary to the bias of the prior art, it hasbeen demonstrated that it is possible to use rapeseed for preparingserum-free and/or protein-free culture media. Even more surprisingly, ithas also been demonstrated that such media comprising peptide extractsderived from rapeseed make it possible not only to obtain a significantincrease in the final concentration of the cells or tissues placed inculture, but also an increase in the specific rate of production of oneor more molecules of interest by cells in culture.

Furthermore, the fact that such an increase in the final cell or tissueconcentration is not linked solely to a nutritional effect has also beendemonstrated.

According to a preferred aspect, the present invention relates to theuse of an extract as described above, characterized in that said peptideextract performs a function in terms of increasing the cell or tissueconcentration and/or in terms of increasing the lifespan of the cellsand/or in terms of the specific rate of production of one or moremolecules of interest, said function being bound not solely by theelemental amino acid composition, but by the composition, of said aminoacids, in peptide form.

This particularly positive effect was established in comparison with theeffect caused by a medium of elemental composition, i.e. consisting offree amino acids, identical in all respects to the composition of thepeptide extract that is the subject of the invention, except for thefact that, in the extract according to the invention, the amino acidsare in peptide form. This point will be established more clearly in thelight of the examples hereinafter.

In general, it emerges from the prior art that the culture media used todate have been prepared with the aim of providing the cells or tissueswith nutrients, and especially amino acids, required by the cell as asource of energy and as a source of carbon and nitrogen. These aminoacids are generally present in the culture media in mainly free aminoacid form. Some amino acids are present in dipeptide or tripeptide formin order to give them sufficient stability in a liquid medium (WO96/26266).

The present invention shows, entirely surprisingly, that the peptideextract that is the subject of the invention and is obtained bysuccessive fractionations of a starting material derived from rapeseed,performs a function that promotes growth of the cells or tissues inculture and helps keep them alive. In fact, as will emerge more clearlyfrom the examples described hereinafter, it has been shown that, for thesame amounts of each amino acid, it is necessary for the latter to be inthe form of peptides in order for an increase in the concentration, andmore particularly an increase in the lifespan of the cells or tissuesand in the specific rate of production of one or more molecules ofinterest, to be observed. It appears that the invention is based notonly on amounts of free amino acids, but on a given composition ofpeptides, preferably di-, tri-, tetra- or pentapeptides.

Without wishing to be bound by any theory, it would seem to be probablethat the extract that is the subject of the present invention does notsolely play a positive role on growth, but also has a role in terms ofreducing the induction of apoptosis.

According to another aspect, the present invention relates to the use ofa peptide extract for preparing and/or supplementing a protein-free invitro cell or tissue culture medium, said extract being obtained bysuccessive fractionations of a plant starting material, characterized inthat said plant starting material consists of rapeseed.

In a manner similar to the serum-free medium described above, the use ofthe peptide extract as described above is characterized in that saidpeptide extract performs a function in terms of increasing the cell ortissue concentration and/or in terms of increasing the lifespan of thecells and/or in terms of the specific rate of production of one or moremolecules of interest, said function being bound not only by theelemental amino acid composition, but by the composition, of said aminoacids, in peptide form.

The expression “protein-free” should not be understood to mean a mediumcompletely devoid of proteins, but a medium completely devoid of proteinof animal origin. This expression encompasses, inter alia, the namesADCF (animal derived component free) or alternatively “animal proteinfree”.

In fact, the presence of proteins is generally necessary for the growthof cells or tissues. The important point, as mentioned above, lies inthe absence of protein of animal origin. Such a culture medium makes itpossible to eliminate, even more radically than serum-free media, anyrisk of contamination by a molecule, or part of such a molecule, thatwould be of animal origin.

According to a preferred embodiment, the invention is directed towardthe use as described above, said use being characterized in that theplant starting material consists of rapeseed cake.

The term “cake” should be understood to mean the solid residue obtainedwhen oil-yielding seeds and fruit are treated for the purpose ofextracting oil (definition in the Petit Larousse Illustré, 1989, page975). One advantage of the present invention therefore lies in the lowcost of the starting material used. In fact, cakes constitute, in alloil-yielding crops, the coproducts obtained, and not given much worth todate, by the oil industry. The present invention therefore provides anapproach for recovering and increasing the value of oil industry waste.

The peptide extracts that are the subject of the present invention arepreferably obtained by hydrolysis of rapeseed cakes. A fractionationprocess for obtaining such extracts has been developed. FIG. 1represents a flowsheet diagram of a preferred process. Of course, anymodification, that is obvious to those skilled in the art, of thisprocess, is part of the present invention.

More particularly, this process comprises six successive stepscorresponding respectively to:

Step 1: Protein Extraction

The objective of this step is the production of a concentrate ofrapeseed proteins, in order to have a starting material enriched inrapeseed proteins (70-80% of protein material relative to solids,against 30-40% in the rapeseed cake).

Step 2: Hydrolysis

The aim of this step is to hydrolyze the proteins in order to obtain asolution consisting of peptides.

Here also, the process used is conventional. The use of Alcalase®, whichis an enzyme preparation of microbial origin, consequently has no riskof transmission of biological elements of animal origin (viruses thatare pathogenic against animal cells, prions, etc.). Hydrolysis time: 5hours, T°=60° C., pH=9, enzyme concentration/substrate concentrationratio=1/10. Free amino acid content of the hydrolyzate: 4% by mass.

Step 3: Acid Precipitation, pH 4

This step is aimed at eliminating the “large” molecules, essentiallylarge proteins and peptides, present in the hydrolyzate, thereby makingit possible to reduce clogging during the subsequent filtration steps.

Step 4: Ultrafiltration with a Membrane Having a Cutoff Threshold of 3kDa

The objective of this step is to recover the small peptides byelimination of the molecules greater than 3000 Da in size (phenoliccompounds such as tannins and polypeptides). The process used is aconventional membrane process for enriching in small peptides containedin a hydrolyzate.

Step 5: Nanofiltration with a Membrane Having a Cutoff Threshold of 500Da

The aim is to reduce the amount of free amino acids in the small-peptidesolution obtained after step 4 and to desalify this same solution inorder to reduce the osmolarity of the mixture. A conventionaldesalification process is used. An 80% reduction in salt concentrationallows better fractionation of the peptides according to their charge instep 5.

Step 6: Ultrafiltration with a Membrane Having a Cutoff Threshold of 1kDa

This step involves fractionating the small peptides according to theirsize and their charge.

This step is particularly advantageous in the sense that it is based onthe use of an ultrafiltration membrane for the purpose of fractionating,according to their size and their charge, the peptides contained in aplant hydrolyzate. Compared with the permeate, the final retentate,corresponding to the peptide extract according to the invention, has ahigher content of peptides containing acidic amino acids, and a lowercontent of peptides containing basic amino acids.

It should be noted that the process described above is given only by wayof illustration of one embodiment, but is in no way limiting. Anymodification or improvement in the latter should be considered to bepart of the present invention.

In order to more thoroughly characterize the peptide extracts, that arethe subject of the present invention, several studies and assays havebeen carried out, the detailed protocols and results of which arepresented later on in the examples. However, it emerges that the peptideextract used in the context of the invention is characterized in that itconsists of at least 80%, preferably at least 90%, by mass ofnitrogenous material.

The expression “nitrogenous material” is intended to denote, in thepresent description, any material consisting of amino acids, it beingpossible for the latter to be in free form or associated as peptides orproteins.

Such a concentration of nitrogenous material, from an oil-yielding plantwith a low protein content, and more particularly rapeseed, is obtainedby means of the process described above. This characteristic is veryadvantageous in the sense that most plant extracts for supplementing aculture medium have much lower contents of nitrogenous material. By wayof example, the cereal-derived extracts described in the patentapplication in the name of QUEST INTERNATIONAL (WO 96/26266) havenitrogenous material contents of, respectively, 54% for the soybeanextracts, 75% for the wheat extracts and 69% for the rice extracts.

The present invention therefore differs from the prior art by virtue ofthe high content of nitrogenous material of the peptide extract used.

In addition, it has also been demonstrated by the inventors that saidnitrogenous material comprises few free amino acids, but consist mainlyof very small peptides. For the protocols and results, reference shouldbe made to the examples hereinafter.

More particularly, the use according to the invention is characterizedin that said nitrogenous material consists of approximately 50% toapproximately 60% of peptides having a molecular size of less than 500daltons.

It is generally accepted that peptides of less than 500 daltons aremainly in the form of di-, tri-, tetra- or pentapeptides. In fact, theaverage molar mass of amino acids is approximately 150 g/mol, with thelowest corresponding to 75.1 g/mol for glycine and the highest to 204.2g/mol for tryptophan.

According to a further aspect of the invention, the use is characterizedin that said nitrogenous material consists of approximately 20% toapproximately 30% of peptides having a molecular size of between 500 and1000 daltons.

Still in the interests of characterizing the peptide extract which isthe subject of the present invention, it has been demonstrated that saidextract has a high content of acidic amino acids.

More particularly, the present invention therefore relates to the use asdescribed above, characterized in that said extract comprises between 20and 40 mol % of aspartic acid and of glutamic acid and/or of theirrespective amides.

Finally, the invention is characterized in that said peptide extractcomprises less than 1% by mass of phenolic compounds.

More particularly, said peptide extract has the following total aminoacid composition:

Amino acids mol % Alanine 2-6 Arginine 5-9 Aspartic acid + asparagine10-14 Cysteine 0 Glutamic acid + glutamine 15-19 Glycine  7-11 Histidine1-5 Isoleucine 2-6 Leucine 5-9 Lysine 2-6 Methionine 0-3 Phenylalanine1-5 Proline 3-7 Serine 5-9 Threonine 5-9 Tryptophan not determinedTyrosine 1-5 Valine 5-9

The percentages indicated in the table above consist of averages, ofwhich the methods of measurement are clearly detailed in the examples.Various preferred concentrations will also be illustrated in the sameexamples.

According to a preferred embodiment, the use according to the inventionis characterized in that said cells consist of eukaryotic cells,preferably animal cells.

By way of nonlimiting example of preferred eukaryotic cells, mention maybe made of the cells used in the industry, for instance CHO, BHK, NSO,PER C6, VERO, HEK293, etc. cells.

According to another aspect, the present invention is not limited to theuse of a peptide extract as described above as supplementation element,but it also relates to a serum-free culture medium.

More particularly, the present invention is directed toward a serum-freecell or tissue culture medium obtained by using, or comprising, apeptide extract as described above.

As mentioned above, the culture media preferably consist of a “basal”medium selected according to the type of culture desired, to which areadded sera or else supplements such as hydrolyzates. The culture mediumthat is the subject of the present invention is distinguished by thevery nature of the extract added, i.e. an extract derived fromoil-yielding plants, more particularly from rapeseeds, as describedabove.

The “basic” media used therefore depend on the nature of the desiredculture. By way of nonlimiting examples, mention may be made of thefollowing media: RPMI (Roswell Park Memorial Institute), MEM (MinimumEssential Medium), Iscove's, IMDM (Iscove's Modified Dulbecco's medium),Ham's, NCTC, TC100, Grace, etc.

In practice, the extracts according to the invention are used in theform of solutions in which the concentrations of these same peptideextracts can vary according to the type of culture desired. By way ofnonlimiting example, in the case of a culture of CHO (Chinese hamsterovary) type cells, the preferred concentrations are of the order of from2 to 6 g/l, preferably 4 g/l. As will emerge from the exampleshereinafter, a lower concentration is not sufficient and a higherconcentration leads to an inhibition of cell growth or potentially cellapoptosis.

For the examples hereinafter, the reference medium used is RPMI 1640medium (SIGMA-ALDRICH).

According to one embodiment, the culture medium according to theinvention is characterized in that it also comprises vitamins, inorganicsalts, free amino acids, organic acids and/or sugars.

The present invention also covers the use of a culture medium accordingto the present invention, for the bulk culturing of cells or tissues.

According to another aspect of the present invention, a culture mediumthat is not only serum-free, but also protein-free, i.e., as explainedabove, devoid of animal proteins, is also covered.

A subject of the present invention is also a protein-free cell or tissueculture medium obtained by using, or comprising, a peptide extract asdescribed above.

In a manner similar to that which has been described above for theserum-free media, according to one embodiment, the protein-free culturemedium according to the invention can also comprise vitamins, inorganicsalts, free amino acids, organic acids and/or sugars.

The invention also covers the use of a protein-free culture mediumaccording to the present invention, for the bulk culturing of cells ortissues.

According to another embodiment, the present invention relates to amethod of in vitro cell or tissue culture. As regards the actual stepsof the method, mention may be made, by way of nonlimiting example, of i)static-mode culturing on a very small scale (96-well plates), ii)static-mode culturing on slightly larger scales (25 cm², 75 cm² and 175cm² culture flasks), then iii) agitated-mode culturing on increasingscales (Erlenmeyer flasks, spinners and cell cultivators that arecontrolled). More particularly, the seeding can be carried out by anyconventional technique known to those skilled in the art.

More particularly, the present invention is directed toward a method ofin vitro cell or tissue culture in a medium devoid of serum,characterized in that it consists in seeding said cells or tissues intoa medium comprising a peptide extract obtained by successivefractionations of a plant starting material, said plant startingmaterial consisting of rapeseed.

One embodiment consists in carrying out the fractionation processdescribed above so as to obtain an extract having the listed properties.

More particularly, the method according to the invention ischaracterized in that said starting material consists of rapeseed cake.

Even more particularly, the method according to the invention ischaracterized in that said extract consists of at least 80%, preferablyat least 90%, by mass of nitrogenous material.

More particularly, the method according to the invention ischaracterized in that said nitrogenous material consists ofapproximately 50% to approximately 60% of peptides having a molecularsize of less than 500 daltons.

Even more particularly, the method according to the invention ischaracterized in that said nitrogenous material consists ofapproximately 20% to approximately 30% of peptides having a molecularsize of between 500 and 1000 daltons.

Preferably, the method according to the invention is characterized inthat said extract comprises between 20 and 40 mol % of aspartic acid andof glutamic acid and/or of their respective amides.

Finally, even more preferably, the method according to the invention ischaracterized in that said extract has the following total amino acidcomposition:

Amino acids mol % Alanine 2-6 Arginine 5-9 Aspartic acid + asparagine10-14 Cysteine 0 Glutamic acid + glutamine 15-19 Glycine  7-11 Histidine1-5 Isoleucine 2-6 Leucine 5-9 Lysine 2-6 Methionine 0-3 Phenylalanine1-5 Proline 3-7 Serine 5-9 Threonine 5-9 Tryptophan not determinedTyrosine 1-5 Valine 5-9

In a manner similar to the culture media as described above, anotheraspect of the invention concerns a method of in vitro cell or tissueculture, said method being characterized in that it is in a protein-freemedium.

More particularly, the method of in vitro cell or tissue culture in aprotein-free medium is characterized in that it consists in seeding saidcells or tissues into a medium comprising a peptide extract obtained bysuccessive fractionations of a plant starting material, said plantstarting material consisting of rapeseed.

In a manner similar to the method of culture in a serum-free medium, thepresent method of culture in a protein-free medium is characterized inthat said starting material consists of rapeseed cake.

More particularly, the method according to the invention ischaracterized in that said extract consists of at least 80%, preferablyat least 90%, by mass of nitrogenous material.

Even more particularly, the method according to the invention ischaracterized in that said nitrogenous material consists ofapproximately 50% to approximately 60% of peptides having a molecularsize of less than 500 daltons.

Preferably, the method according to the invention is characterized inthat said nitrogenous material consists of approximately 20% toapproximately 30% of peptides having a molecular size of between 500 and1000 daltons.

Even more preferably, the method according to the invention ischaracterized in that said extract comprises between 20 and 40 mol % ofaspartic acid and of glutamic acid and/or of their respective amides.

More particularly, the method according to the invention ischaracterized in that said extract has the following total amino acidcomposition:

Amino acids mol % Alanine 2-6 Arginine 5-9 Aspartic acid + asparagine10-14 Cysteine 0 Glutamic acid + glutamine 15-19 Glycine  7-11 Histidine1-5 Isoleucine 2-6 Leucine 5-9 Lysine 2-6 Methionine 0-3 Phenylalanine1-5 Proline 3-7 Serine 5-9 Threonine 5-9 Tryptophan not determinedTyrosine 1-5 Valine 5-9

Finally, according to a last aspect of the present invention,particularly advantageous properties have been demonstrated with regardto the adapation of a medium with serum to a medium according to theinvention. In fact, it may be advantageous, for various reasons known tothose skilled in the art, for instance (i) the obtaining of new celllines by genetic modification (transfection), (ii) a higher cellviability during thawing subsequent to freezing in a medium containingserum, (iii) higher growth and (iv) greater resistance of the cells toshear forces, to start a culture in a medium with serum and, more orless rapidly, to switch this culture into a medium devoid of serumand/or protein-free. It is known that such transfers are difficult toimplement since the cells have trouble withstanding such a change whichconstitutes a stress for them, which, in most cases, is fatal to them.In order to avoid such a stress, the cells are gently transferred intomedia comprising decreasing concentrations of serum so as to gentlyadapt the cells to the new serum-free medium. Such a period, referred toas adaptation period, is relatively long and tedious.

Entirely surprisingly, the inventors have shown that this stress can beavoided by transferring the cultures into a serum-free medium containingthe peptide fraction that is the subject of the invention, evenabruptly. This property of the invention will emerge clearly from theexamples and figures hereinafter.

The present invention therefore relates to a method for directlytransferring an in vitro culture in a medium with serum, to a culture ina serum-free medium, characterized in that it consists in recovering thecells and/or the tissue from the medium with serum, and in seeding themor it directly into a serum-free medium as described in the presentpatent application.

According to yet another advantageous aspect, the present inventionrelates to a method for adapting an in vitro culture in a medium withserum, to a culture in a serum-free medium, characterized in that itconsists in recovering the cells and/or the tissue from the medium withserum, and in seeding them or it, stepwise, into media having decreasingserum concentrations, respectively.

The present invention covers a method of adaptation as described above,characterized in that said method of adaptation comprises the followingfour steps:

-   -   step 1: 75% medium with serum/25% serum-free medium+peptide        extract,    -   step 2: 50% medium with serum/50% serum-free medium+peptide        extract,    -   step 3: 25% medium with serum/75% serum-free medium+peptide        extract,    -   step 4: 100% serum-free medium+peptide extract.

According to another aspect, a subject of the invention is a method fordirectly transferring an in vitro culture in a medium with serum, to aculture in a protein-free medium, characterized in that it consists inrecovering the cells and/or the tissue from the medium with serum, andin seeding them or it directly into a protein-free medium as describedin the present invention.

According to a further embodiment, the present invention covers a methodfor adapting an in vitro culture in a medium with serum, to a culture ina protein-free medium, characterized in that it consists in recoveringthe cells and/or the tissue from the medium with serum, and in seedingthem or it, stepwise, into media having decreasing serum concentrations,respectively.

More particularly, the method of adaptation according to the inventionis characterized in that said method of adaptation comprises thefollowing four steps:

-   -   step 1: 75% medium with serum/25% serum-free medium+peptide        extract,    -   step 2: 50% medium with serum/50% serum-free medium+peptide        extract,    -   step 3: 25% medium with serum/75% serum-free medium+peptide        extract,    -   step 4: 100% serum-free medium+peptide extract.

Finally, according to a last aspect, a subject of the present inventionis a method for adapting an in vitro culture in a medium with serum, toa culture in a protein-free medium, characterized in that said methodcomprises the following steps:

-   -   step 1: carrying out the method that is the subject of the        invention,    -   step 2: recovering the cells and/or the tissues from the        serum-free medium,

step 3: seeding said cells and/or tissues directly into a protein-freemedium.

The advantages of the present invention will be demonstrated in thelight of the examples and figures hereinafter, in which:

FIG. 1 represents a flowsheet of an embodiment of a method for obtainingthe peptide extract in accordance with the invention;

FIG. 2 represents the effect of a sterilizing filtration on the extractaccording to the invention;

FIG. 3 represents, in the form of a histogram, the effect of theconcentration of the extract according to the invention on the maximumcell density;

FIG. 4 illustrates the adaptation of VERO cells from a medium withserum, to a serum-free medium and to a protein-free medium comprisingthe extract according to the invention;

FIG. 5 illustrates the adaptation of hybridoma-type cells from a mediumwith serum, to a serum-free medium comprising the extract according tothe invention;

FIG. 6 illustrates the adaptation of CHO K1 dhfr⁻ cells from a mediumwith serum, to a serum-free medium and to a protein-free mediumcomprising the extract according to the invention;

FIGS. 7A and 7B illustrate the adaptation of CHO C5 cells from aserum-free medium to a serum-free medium and to a protein-free mediumcomprising the extract according to the invention;

FIG. 8 represents the change in the concentration of viable cells overthe course of prolonged cultures of CHO C5 cells;

FIGS. 9, 10 and 11 illustrate the effect of the extract according to theinvention on the specific rate of production of interferon by culturedCHO C5 cells; and

FIG. 12 demonstrates that the function of the extract according to theinvention is not linked solely to the elemental amino acid composition,but to the composition, of said amino acids, in peptide form.

EXAMPLE 1 Protocols for the Method for Generating the Peptide Extractwhich is the Subject of the Invention

The protocol described hereinafter is illustrated by FIG. 1. Moreparticularly, the present example reiterates all the steps, providingdetails of them, according to one of the preferred embodiments. It isclearly understood that variations, obvious to those skilled in the art,may be introduced into this method.

Step 1: Protocol for Rapeseed Protein Extraction

The protocol followed for this step is represented in the scheme below.

The plant proteins used are a deoiled industrial meal, which is aresidue from the oil industry (Novance, Compiègne, France), containing35% by weight of nitrogenous material. Starting from this substrate, aprotein concentrate is prepared (75% of nitrogenous material) byextraction with sodium hydroxide and acid precipitation at theisoelectric pH of the proteins (pH 4).

The total yield of proteins from the method for obtaining theconcentrate from the rapeseed cake is approximately 28%.

The composition of the concentrate obtained is the following (see Table1).

TABLE 1 Composition of the concentrate obtained Proteins Fiber LipidsAsh Others Content (%) 75 14 5 3 3

Step 2: Protocol for Hydrolysis of the Rapeseed Cake Protein Concentrate

Use of Alcalase 2.4 L®, which is an enzyme preparation of microbialorigin, at an enzyme concentration-/substrate concentration ratio=1/10.

The concentrate is hydrolyzed enzymatically in a thermostated (60° C.)stirred reactor, through the action of Alcalase 2.4 L® (NovoNordisk,Bagsvaerd, Denmark), with pH regulation (pH 9 maintained by addingsodium hydroxide). After 5 hours of hydrolysis, corresponding to adegree of hydrolysis of 28% (pH-stat technique), the reaction is stoppedby inactivation of the enzyme (90° C. for 10 min).

Step 3: Acid Precipitation, pH 4

The pH of the hydrolyzate obtained at the end of step 2 is then loweredto 4 in order to precipitate the large molecules and concentrate thepeptides in the supernatant. This new step makes it possible toeliminate the large molecules responsible for clogging during thesubsequent filtration steps, and to concentrate the relatively smallpeptides.

Step 4: Ultrafiltration with a Membrane Having a Cutoff Threshold of 3kDa

The objective of this step is to purify the small peptides byeliminating the molecules greater than 3000 Da in size (phenoliccompounds+polypeptides).

The process uses a conventional regenerated cellulose membrane forconcentrating the peptides of theoretical molar mass less than 3000g/mol.

Step 5: Nanofiltration with a Membrane Having a Cutoff Threshold of 500Da

The objective of this step is to decrease the amount of free amino acidsin the small-peptide solution obtained after step 4, and to desalifythis same solution in order to reduce the osmolarity of the mixture.

This separation step, which involves a membrane consisting of apolyamide/polysulfone composite film, results in an 80% reduction in thesalt concentration, thereby allowing better fractionation of thepeptides according to their charge in the following step 6.

Step 6: Ultrafiltration with a Membrane Having a Cutoff Threshold of 1kDa

The objective is to fractionate the small peptides according to theirsize and their charge.

A conventional regenerated cellulose membrane is used with the aim offractionating, according to their size but also according to theircharge, as a function of the conditions under which the membrane isused, the peptides recovered after step 5, the molar masses of whichshould theoretically be between 500 and 3000 g/mol.

The realization of this step produces two fractions:

-   -   a permeate containing essentially peptides of molar mass        theoretically less than 1000 g/mol,    -   a retentate which, compared to the permeate, has, firstly, a        higher content of peptides containing acidic amino acids and,        secondly, a lower content of peptides containing basic amino        acids.

The peptide extract that is the subject of the present inventionconsists of the retentate obtained by carrying out the method asdescribed above.

Modifications can obviously be introduced. By way of nonlimitingexample, it is possible to envision adjusting the pH to 4 during steps 5and 6, instead of 9, or alternatively eliminating step 5.

EXAMPLE 2 Protocols Implemented for Characterizing the Extract that isthe Subject of the Invention

2.1 Assaying nitrogen by the Kjeldahl Method

Reagents

-   -   Mineralization catalyst (17% Na₂SO₄; 1.5% CuSO₄.5H₂O; 1.5%        salts): Prolabo, 22550-293    -   1N H₂SO₄: Labosi A4715891    -   35% H₂O₂: Labosi, A4823251    -   40% NaOH: Merck, 191537    -   H₃BO₃: Labosi, A4703851

Material

-   -   Vapodest 4 titramatic automatic Kjeldahl apparatus: Gerhardt        GmbH & Co. KG, Bonn, Germany.    -   645 Multi-dosimat automatic titration system: Metrohm, Herisau,        Switzerland.    -   Kjeldatherm® KT 12 S mineralization block: Gerhardt GmbH & Co.        KG, Bonn, Germany.

Assay Protocol

The protein content was determined by the Kjeldahl method. This assaymethod is based on the conversion of organic nitrogen to inorganicnitrogen in the form of ammonium sulfate (NH₄)₂SO₄. The assay is carriedout automatically with the Vapodest 4S. For each sample, the analysis isperformed twice so as to be able to calculate an average value. It isalso necessary to perform an assay on a blank, in order to obtain, aftersubtraction, a value for the total nitrogen really contained in thesample.

The results are expressed as nitrogen concentration by mass, accordingto the formula: amount of nitrogen (g/l)=(V−V0)×N×14/E

with

-   -   V: volume of H₂SO₄ required to titrate the sample, in ml,    -   V₀: volume of H₂SO₄ required to titrate the blank, in ml,    -   N: H₂SO₄ solution titer (mol/l),    -   E: sample size in mg or in ml.

The protein percentage is obtained by means of the conversioncoefficient for rapeseed proteins (6.25), itself calculated from thenitrogen content of these proteins (16%): amount of proteins=6.25×amountof nitrogen. It emerges from this calculation that the % protein of theextract which is the subject of the invention is approximately 90% (seeTable 2 hereinafter).

2.2. Acid Hydrolysis of Peptides and Assaying of Amino Acids

Reagents

-   -   trichloroacetic acid at 50% (w/v) in water: Prolabo, 20734.295    -   9-fluorenylmethyl chloroformate (FMOC-Cl): OSI, A4 700.792,    -   2.5 mg/ml in acetonitrile: Fluka, 23184    -   o-phthalaldehyde (OPA): Fluka, 79760    -   3-mercaptopropionic acid (3-MPA): Sigma, M-6750    -   10 mg of each of the compounds (OPA and 3-MPA) in 1 ml of 0.4 N        borate buffer, pH 10.5: Hewlett-Packard, 5061-3339    -   standard solution of a mixture of amino acids: Sigma, AA-S-18    -   2N NaOH solution: Fluka, 72071    -   6N HCl: Labosi, A4715801

Eluting Solutions:

Solvent A: 20 mM of sodium acetate. 3 H₂O (OSI, 27652.298), containing0.024% (v/v) of triethylamine (OSI, 28 745.296) and 0.5% (v/v) oftetrahydrofuran (OSI, 28 556.293). The mixture is adjusted to pH 7.2with acetic acid (OSI, 20 104.298).

Solvent B: 20% (v/v) of a 100 mM sodium acetate buffer (OSI, 27 652.298)adjusted to pH 7.2 with acetic acid, 40% (v/v) of acetonitrile and 40%(v/v) of methanol (Prolabo, 20 865.322).

Material

-   -   0.22 μm single-use filters: Schleicher & Schuell, Dassel,        Germany    -   incubator model 700: Memmert, Schwabach, Germany    -   Hypersil C18 column: Interchim, H5 C18-20R, Montluçon, France    -   HP 1090 chromatography system: Hewlett Packard, Palo Alto,        United States.

Method

An acid hydrolysis of the peptide fractions is carried out beforehand inorder to obtain a homogeneous mixture of free amino acids. A sample of 1g or of 1 ml is placed in a stoppered test tube. 4 ml of hydrochloricacid (6 N) are then added and the test tube is then placed in a nitrogenatmosphere before being hermetically closed. The hydrolysis is thencarried out in an incubator at 110° C. for 24 h. After cooling, thehydrolyzates are neutralized to a pH of approximately 6 by adding 4Nsodium hydroxide. The samples are finally filtered through a 0.22 μmsyringe filter.

The disadvantage of acid hydrolysis is the destruction of the tryptophanand the conversion of glutamine and asparagine to glutamic acid andaspartic acid, respectively. The tryptophan analysis can be carried outafter an alkaline hydrolysis, by ion exchange chromatography (Hugli T.E. et al., 1972, Determination of the tryptophan content of proteins byion exchange chromatography of alkaline hydrolysates, Ibid., 247,2828-2834). Given that the amount of tryptophan is very limited inrapeseed (Godon B., 1996, Les méthodes courantes de laboratoire pour laséparation et l′ analyse des protéines végétales [Current laboratorymethods for the separation and analysis of plant proteins]. In:publisher Lavoisier. Protéines végétales [Plant proteins], 65-80), thisamino acid is not analyzed. As regards the glutamine and asparagine,their quantification will be integrated with the corresponding acidicamino acids, in the forms Glx and Asx (Glx=Gln+Glu, Asx=Asn+Asp).

Protocol

The amino acids and the alanyl-glutamine and glycyl-glutamine dipeptidesare assayed by reverse-phase liquid chromatography after derivatizationin the presence of o-phthalaldehyde (OPA) and 9-fluorenyl-methylchloroformate (FMOC). The principle of the derivatization is thefollowing: the primary amino acids are placed in the presence of OPA and3-mercapto-propionic acid (3-MPA), to give isoindoles that are highlyfluorescent and absorbent in the UV range (338 nm) (Godel et al., 1992,Automated amino acid analysis using combined OPA and FMOC-Cl precolumnderivatization, LC-GC INTL., 5, 44-49).

According to the same principle, the secondary amino acids arederivatized in the presence of FMOC, to give derivatives that are highlyfluorescent and absorbent in the UV range (262 nm). The detectionthreshold is of the order of 100 pmol.

The samples are automatically derivatized using a Hewlett Packard HP1090 liquid chromatograph system. 3 μl of sample are first of allneutralized with 1.5 μl of 2 N NaOH, in order to obtain completederivatization. The whole is then mixed with 6.0 μl of 0.4 N boratebuffer, 2.5 μl of the solution of OPA+3-MPA and 2.5 μl of the FMOCsolution. The mixing lasts 15 min in order to allow the derivatization;finally, the whole is injected onto the Hypersil C18 separating column.The eluting solvent is composed of 100% solution A for 17 min, then of40% of solution A and 60% of solution B for 1 min and, finally, of 100%of solution B for 7 min. The amino acids are separated according totheir polarity; the most polar come off the column at the beginning ofanalysis and the least polar at the end of analysis. As they come offthe column, the primary amino acids and the dipeptides are detected bymeans of a UV detector at 338 nm, and the secondary amino acids aredetected by means of a UV detector at 262 nm. The total analysis time is25 min.

The determination of the amount of free amino acids is carried outaccording to the same protocol, except for the absence of an acidhydrolysis step.

Before sample analysis, three solutions, containing 17 amino acids atconcentrations of 0.25, 0.5 and 2.5 mM respectively, are derivatized andinjected without prior neutralization with 2 N NaOH. The profilesobtained serve to establish a standard range for each amino acid, whichthen makes it possible to determine the concentration of each amino acidcontained in a sample after integration of the peaks (Hewlett Packardsystem).

2.3. Assaying of the Solids

The water content was determined by bringing the samples (1 to 5 g) to105° C. in an incubator until a constant mass was obtained.

2.4. Determination of the Size of the Peptides by Size ExclusionChromatography

Material

-   -   Superdex peptide HR 10/30 column (7000-200 Da): Amersham        Biosciences, Uppsala, Sweden    -   0.22 μm Minisart RC 25 filters: Sartorius, Goettingen, Germany    -   vacuum filtration device, sintered glass funnel SM 16309:        Sartorius, Goettingen, Germany    -   BioCAD® 700^(E) chromatography system: Applied Biosystems,        Foster City, United States    -   fraction collector model 203B: Gilson, Middleton, United States.

Method

The operating conditions are the following:

-   -   eluent: ACN/H₂O/TFA (40/60/0.1—v/v/v), filtered through 0.45 μm    -   solvent degassed with helium: 5 ml/min    -   eluent flow rate: 0.6 ml/min    -   column temperature: ambient (25° C.)    -   detection: UV at 214 nm    -   injected volume: 50 μl    -   analysis time: 45 min

The column was pre-calibrated with peptides of known molar masses. Twostraight lines were obtained by plotting the logarithm of the molar massas a function of the retention time. The determination of therelationship linking the molar mass (MM) of the molecules to theirretention time on the column made it possible to define the distributionaccording to the size of the peptides contained in the variousfractions.

2.5. Assaying the Phenolic Compounds

The amount of phenolic compounds in the fractions was estimated assinapic acid equivalent. Sinapic acid (Sigma, D 7927), with a molar massof 224 g/mol, was used as reference because it is the phenolic acidpredominantly present in the rapeseed cake (between 70 and 90%)according to Naczk M. et al., 1992, Recovery of rapeseed tannins byvarious solvent systems, Food Chem., 45, 51-54.

The calibration and the measurements were carried out using the samechromatographic conditions as those used in size-exclusion HPLC, exceptfor the detection wavelength fixed, in this case, at 310 nm, whichcorresponds to the maximum absorption wavelength for this acid(Sakakibara H. et al., 2003, Simultaneous determination of allpolyphenols in vegetables, fruits and teas, J. Agric. Food Chem., 51,571-581). The amount of phenolic compounds in each fraction wasexpressed in mg of sinapic acid equivalents/100 g of solids. The contentof free phenolic compounds was estimated by calculating the proportionof the area under the peak having a retention time (between 34 and min)identical to that of the standard used to establish the calibrationcurve.

The results of Example 2 are given in the tables below:

Composition of the Nitrogenous and Phenolic Material of the PeptideExtract: (see Table 2)

TABLE 2 Peptide % free amino Amount of polyphenols content acids/PM(mg/100 g S) Extract 90% 3% 31% tannins 65% bound phenolic acids 4% freephenolic acids PM: peptide material; S: solids.

Peptide Size Distribution (Relative to Total Peptide Material): (seeTable 3)

TABLE 3 Size (Da) >5000 5000-1000 1000-500 <500 Extract 0% 20% 23% 57%

Amino Acid Composition of the Peptide Extract (3 Analyses): (see Table4)

TABLE 4 aa % % % Asx 13 12 12 Glx 17 17 20 Ser 7 7 5 His 3 3 2 Gly 9 9 9Thr 7 7 5 Ala 4 4 5 Arg 7 7 7 Tyr 2 3 3 Cys 0 0 0 Val 7 7 8 Met 1 1 0Phe 3 3 3 Ile 4 4 4 Leu 7 7 7 Lys 4 4 4 Pro 5 5 6 100 100 100 Asx:aspartic acid + asparagine Glx: glutamic acid + glutamine

In all of Examples 4 to 9 hereinafter, and unless otherwise indicated inthe text, the cultures were carried out with CHO-C5 cells in thefollowing culture media:

Reference medium (o)=RPMI 1640 (Sigma)+BITS+ET+glutamine

Medium of interest (Δ)=reference medium+4 g/l of peptide extractaccording to the invention.

EXAMPLE 3 Effect of a Sterilizing Filtration

The culture system used consists of a 125 ml Erlenmeyer flask, Vu=25 ml.

CHO-C5 cells were cultured in reference medium (o) or in medium ofinterest (Δ) sterilized once ((open symbols) or 3 times (solid symbols)by 0.22 μm sterilizing filtration.

The results obtained are represented in FIG. 2.

It emerges from the latter that there is no decrease in the effect ofthe peptide extract according to the invention when 0.22 μm filtrationis carried out.

EXAMPLE 4 “Cryoprotective” Effect of the Peptide Extract According tothe Invention (see Table 5)

The culture system used consists of static culture flasks.

TABLE 5 Duration of storage period at −196° C. 1 week 1 month 5 monthsTime after thawing and placing in culture again (h) 0 24 48 96 0 24 4896 0 24 48 96 120 % Reference 61 44 60 81 46 33 36 65 44 34 36 53 72viability M. M of 64 52 56 85 58 46 55 74 39 38 45 68 92 interest

A better recovery of the cells frozen in the presence of the extractaccording to the invention is observed. This property is particularlyadvantageous in the sense that, in practice, the cells are often frozenand then thawed in order to be, for example, conserved or elsetransported.

EXAMPLE 5 Effect of the Concentration of the Extract According to theInvention on Maximum Cell Density

The culture system used consists of 96-well plates, Vu=200 μl. Thegrowth was followed with the Cellscreen apparatus (Innovatis).

The results obtained are given in FIG. 3.

These results show that the concentration of 4 g/l is the one thatprovides the best results. Concentrations that are too high compromisethe growth. Without wishing to be bound by any theory, the inventors putforward the hypothesis that the concentration of inhibitors or of toxiccompounds could destroy the positive effect of the activators.

EXAMPLE 6 Assays Relating to Adaptation of Various Cells

6.1. Switching a Medium with 10% of Serum to a Serum-Free MediumContaining the Extract According to the Invention

The culture system used consists of static culture flasks.

6.1.1. VERO Cells (Adherent Cells)

The basic medium used is aMEM. The adaptation carried out is an abruptadaptation. The results obtained are represented in FIG. 4.

The successive passages of VERO cells, illustrated by the curve (Δ),represent the adaptation in the presence of extract according to theinvention. The curve (o) represents the adaptation of the cells in theabsence of extract. From D0 to D17, the FCS is decreased from 10 to 1%.At D17, the FCS is abruptly eliminated and replaced with the mixture(peptide extract according to the invention, BITS, ET, Q). At D36, theBITS are eliminated.

It emerges from the results obtained that, in the absence of peptideextract in accordance with the invention, the adaptation is impossible(the cells are dead within two passages). In the presence of saidextract and of BITS, the adaptation of the cells is rapid (recovery ofgrowth at the 3^(rd) passage). In the presence of this same extract andin the absence of animal proteins (protein-free medium), the adaptationis slightly more difficult, but remains possible.

In the presence of BITS and of peptide extract and in the absence ofserum, the VERO cells remain adherent. When the BITS are removed, thesecells also remain adherent, but to a lesser degree (the time requiredfor trypsinization is greatly decreased).

6.1.2. Hybridomas (Cells in Suspension)

The basic medium used is RPMI.

Abrupt Adaptation

In the case of an abrupt adaptation, the death of the cells is rapidlyobserved when the FCS is abruptly substituted with the mixture (peptideextract+BITS+ET+Q).

Gentle Adaptation

Successive passages of hybridoma cells were carried out. The resultsobtained are illustrated in FIG. 5, in which the curve (Δ) representsthe adaptation in the presence of extract according to the invention andthe curve (o) represents the adaptation of the cells in the absence ofextract according to the invention. From D0 to D17, the FCS is decreasedfrom 10 to 1%. From D17 to D35, the FCS is gradually eliminated andreplaced with the mixture (peptide extract, BITS, ET, Q). At D47, theBITS are eliminated.

The results obtained show that, in the absence of peptide extract, theadaptation is impossible (the cells are dead within 2 passages in the25%/75% mixture). In the presence of extract and of BITS and in theabsence of serum, the hybridomas adapt correctly (recovery at the 4^(th)passage). Elimination of the animal proteins (BITS) leads toinstantaneous death of the cells.

6.1.3. CHO K1 dhfr⁻ (CHO DUXB11) (Cells in Suspension)

The basic medium used is αMEM+ribo- and deoxyribonucleosides.

Abrupt Adaptation

The same observations as with the hybridoma cells are reported (data notshown).

Gentle Adaptation

Several successive passages of CHO K1 dhfr⁻ cells were carried out. Theresults obtained are represented in FIG. 6, in which the curve (Δ)represents the adaptation in the presence of peptide extract, whereasthe curve (o) represents the adaptation of the cells in the absence ofpeptide extract. From D0 to D12, the FCS is decreased from 10 to 2%.From D12 to D40, the FCS is gradually eliminated and replaced with themixture (peptide extract, BITS, ET, Q). At D40, the BITS are eliminated.

It emerges from these results that, in the absence of peptide extract,the adaptation is impossible (the cells are dead within 3 passages inthe 25%/75% mixture). In the presence of peptide extract and of BITS andin the absence of serum, the CHO K1 cells adapt correctly (recovery atthe 1^(st) passage). Elimination of the animal proteins (BITS) leads toa slowing down of growth and a longer adaptation (approximately 6passages), but said adaptation remains possible.

6.2. Shifting from a (Reference) Serum-Free Medium to a Serum-FreeMedium with Peptide Extract (Medium of Interest or Medium of Interestwithout Protein of Animal Origin)

6.2.1. Successive Passages of CHO C5 (Cells in Suspension)

The culture system used consists of static culture flasks. Severalsuccessive passages of CHO C5 cells were carried out in reference medium(o), in medium of interest (Δ) and in medium of interest without animalproteins (x). The results obtained for the reference medium are given inFIG. 7A. The results obtained for the media of interest are, for theirpart, represented in FIG. 7B.

It emerges from these figures that the adaptation of the cells to themedium of interest and also the positive effect of the peptide extractare conserved for at least 7 passages. Similarly, the propagation of thecells in the medium without animal proteins makes it possible to obtaincell concentrations close to those observed in reference medium for atleast 7 passages.

It may be concluded that the protein-free medium according to theinvention can be used as a routine medium for maintaining the cells, allthe more so since the cells can be transferred only every 3 days(instead of every 2 days for the reference medium).

6.2.2. Kinetics of Prolonged Cultures (Cells in Suspension)

The culture systems used are spinners of 500 ml, Vu=160 ml.

The change in viable cell concentration over the course of the CHO C5cell cultures carried out, without prior adaptation, is represented inFIG. 8. More particularly, this figure illustrates the cultures inreference medium (o), in reference medium without BITS (-), in medium ofinterest (Δ) and in medium of interest without BITS (x).

It clearly emerges from the results obtained that the reference mediumno longer allows cell growth when the animal proteins are eliminated.The medium of interest makes it possible to virtually double the maximumconcentration. Furthermore, the duration of the culture (beforevirtually complete disappearance of viable cells) is multiplied 3-fold.

The medium of interest allows growth when the animal proteins areeliminated. In the absence of animal proteins, and in the presence ofpeptide extract, the maximum cell concentration is not enhanced, but thelongevity of the culture is increased by a factor 2 relative to thereference medium.

EXAMPLE 7 Effect of the Peptide Extract on the Specific Rate ofProduction of Interferon

The culture system used consists of a 2-liter cell cultivator, usablevolume Vu=1.2 l.

FIG. 9 represents the growth kinetics of CHO C5 cells in referencemedium (o) and in medium of interest (Δ).

FIG. 10, for its part, represents the kinetics of IFN (gamma interferon)production by the same CHO C5 cells in reference medium (o) and inmedium of interest (Δ).

Finally, FIG. 11 illustrates the specific rate of interferon productionby CHO C5 cells in reference medium (dashed line) and in medium ofinterest (solid line).

-   -   The positive effect of the peptide extract on the viable cells        is confirmed on the reactor scale (*3.3).    -   A large increase in final IFN production (*5.3) is noted.    -   This increase may be the combined result of the increase in        viable cells, but also of the increase in the specific rate of        production (maximum value virtually doubled).

EXAMPLE 8 Demonstration of the Function Linked not Solely to theElemental Amino Acid Composition, but to the Composition, of Said AminoAcids, in Peptide Form

The culture system used consists of 500 ml spinners, Vu=160 ml.

FIG. 12 represents the kinetics of viable CHO C5 cells cultured inspinners, in the reference medium (o), the reference medium supplementedwith free amino acids (x) and the medium of interest (Δ). The free aminoacids correspond to the total amino acids present in the peptide extract(peptides and free).

The addition of amino acids in the same proportion as those present inthe peptide extract, in the form of peptides, does not make it possibleto increase the viable cell concentration. On the other hand, a positiveeffect on the longevity of the culture is noted. The composition ofindividual amino acids, equivalent to that of the peptide mixture of thepeptide extract used, contributes towards keeping the cells alive (*3compared with the reference medium).

The peptide extract improves the amount, via a doubling of the viablecell population, but also the viability of the cells (50% additionaltime compared with the reference medium+free amino acids, using themaximum cell concentration obtained in this case as reference point).These results do not appear to be solely generated by an effect linkedonly to the overall amino acid composition. They can also be broughtabout by a “growth factor” effect derived from the presence of certainpeptides, with the specific composition, in the peptide extractaccording to the invention.

1. The use of a peptide extract for preparing and/or supplementing aserum-free in vitro cell or tissue culture medium, said extract beingobtained by successive fractionations of a plant starting material,characterized in that said plant starting material consists of rapeseed.2. The use of a peptide extract for preparing and/or supplementing aprotein-free in vitro cell or tissue culture medium, said extract beingobtained by successive fractionations of a plant starting material,characterized in that said plant starting material consists of rapeseed.3. The use as claimed in claim 1, characterized in that said peptideextract performs a function in terms of increasing the cell or tissueconcentration and/or in terms of increasing the lifespan of the cellsand/or in terms of the specific rate of production of one or moremolecules of interest, said function being bound not solely by theelemental amino acid composition, but by the composition, of said aminoacids, in peptide form.
 4. The use as claimed in claim 1, characterizedin that said plant starting material consists of rapeseed cake.
 5. Theuse as claimed in claim 1, characterized in that said peptide extractconsists of at least 80%, preferably at least 90%, by mass ofnitrogenous material.
 6. The use as claimed in claim 5, characterized inthat said nitrogenous material consists of approximately 50% toapproximately 60% of peptides having a molecular size of less than 500daltons.
 7. The use as claimed in claim 5, characterized in that saidnitrogenous material consists of approximately 20% to approximately 30%of peptides having a molecular size of between 500 and 1000 daltons. 8.The use as claimed in claim 1, characterized in that said extractcomprises between 20 and 40 mol % of aspartic acid and of glutamic acidand/or of their respective amides.
 9. The use as claimed in claim 1,characterized in that said peptide extract comprises less than 1% bymass of phenolic compounds.
 10. The use as claimed in claim 1,characterized in that said peptide extract has the following total aminoacid composition: Amino acids Molar % Alanine 2-6 Arginine 5-9 Asparticacid + asparagine 10-14 Cysteine 0 Glutamic acid + Glutamine 15-19Glycine  7-11 Histidine 1-5 Isoleucine 2-6 Leucine 5-9 Lysine 2-6Méthionine 0-3 Phenylalanine 1-5 Proline 3-7 Serine 5-9 Threonine 5-9Tryptophan not détermined Tyrosine 1-5 Valine 5-9


11. The use as claimed in claim 1, for culturing cells, characterized inthat said cells consist of eukaryotic cells, preferably animal cells.12. A serum-free cell or tissue culture medium obtained by using apeptide extract as claimed in claim
 1. 13. The culture medium as claimedin claim 12, characterized in that it also comprises vitamins, inorganicsalts, free amino acids, organic acids and/or sugars.
 14. The use of aculture medium as claimed in claim 12, for the bulk culturing of cellsor tissues.
 15. A protein-free cell or tissue culture medium, obtainedby using a peptide extract as claimed in claim
 2. 16. The culture mediumas claimed in claim 15, characterized in that it also comprisesvitamins, inorganic salts, free amino acids, organic acids and/orsugars.
 17. The use of a culture medium as claimed in claim 15, for thebulk culturing of cells or tissues.
 18. A method of in vitro cell ortissue culture in a medium devoid of serum, characterized in that itconsists in seeding said cells or tissues into a medium comprising apeptide extract obtained by successive fractionations of a plantstarting material, said plant starting material consisting of rapeseed.19. The method as claimed in claim 18, characterized in that saidstarting material consists of rapeseed cake.
 20. The method as claimedin claim 18, characterized in that said extract consists of at least80%, preferably at least 90%, by mass of nitrogenous material.
 21. Themethod as claimed in claim 18, characterized in that said nitrogenousmaterial consists of approximately 50% to approximately 60% of peptideshaving a molecular size of less than 500 daltons.
 22. The method asclaimed in claim 18, characterized in that said nitrogenous materialconsists of approximately 20% to approximately 30% of peptides having amolecular size of between 500 and 1000 daltons.
 23. The method asclaimed in claim 18, characterized in that said extract comprisesbetween 20 and 40 mol % of aspartic acid and of glutamic acid and/or oftheir respective amides.
 24. The method as claimed in claim 18,characterized in that said extract has the following total amino acidcomposition: Amino acids Molar % Alanine 2-6 Arginine 5-9 Asparticacid + asparagine 10-14 Cysteine 0 Glutamic acid + Glutamine 15-19Glycine  7-11 Histidine 1-5 Isoleucine 2-6 Leucine 5-9 Lysine 2-6Méthionine 0-3 Phenylalanine 1-5 Proline 3-7 Serine 5-9 Threonine 5-9Tryptophan not determined Tyrosine 1-5 Valine 5-9


25. A method of in vitro cell or tissue culture in a protein-freemedium, characterized in that it consists in seeding said cells ortissues into a medium comprising a peptide extract obtained bysuccessive fractionations of a plant starting material, said plantstarting material consisting of rapeseed.
 26. The method as claimed inclaim 25, characterized in that said starting material consists ofrapeseed cake.
 27. The method as claimed in claim 25, characterized inthat said extract consists of at least 80%, preferably at least 90%, bymass of nitrogenous material.
 28. The method as claimed in claim 25,characterized in that said nitrogenous material consists ofapproximately 50% to approximately 60% of peptides having a molecularsize of less than 500 daltons.
 29. The method as claimed in claim 25,characterized in that said nitrogenous material consists ofapproximately 20% to approximately 30% of peptides having a molecularsize of between 500 and 1000 daltons.
 30. The method as claimed in claim25, characterized in that said extract comprises between 20 and 40 mol %of aspartic acid and of glutamic acid and/or of their respective amides.31. The method as claimed in claim 25, characterized in that saidextract has the following total amino acid composition: Amino acidsMolar % Alanine 2-6 Arginine 5-9 Aspartic acid + asparagine 10-14Cysteine 0 Glutamic acid + Glutamine 15-19 Glycine  7-11 Histidine 1-5Isoleucine 2-6 Leucine 5-9 Lysine 2-6 Méthionine 0-3 Phenylalanine 1-5Proline 3-7 Serine 5-9 Threonine 5-9 Tryptophan not determined Tyrosine1-5 Valine 5-9


32. A method for directly transferring an in vitro culture in a mediumwith serum, to a culture in a serum-free medium, characterized in thatit consists in recovering the cells and/or the tissue from the mediumwith serum, and in seeding them or it directly into a medium as claimedin claim
 12. 33. A method for adapting an in vitro culture in a mediumwith serum, to a culture in a serum-free medium, characterized in thatit consists in recovering the cells and/or the tissue from the mediumwith serum, and in seeding them or it, stepwise, into a medium asclaimed in claim 12, said medium having decreasing serum concentrations,respectively.
 34. The method of adaptation as claimed in claim 33,characterized in that said method of adaptation comprises the followingfour steps: step 1: 75% medium with serum/25% serum-free medium+peptideextract, step 2: 50% medium with serum/50% serum-free medium+peptideextract, step 3: 25% medium with serum/75% serum-free medium+peptideextract, step 4: 100% serum-free medium+peptide extract.
 35. A methodfor directly transferring an in vitro culture in a medium with serum, toa culture in a protein-free medium, characterized in that it consists inrecovering the cells and/or the tissue from the medium with serum, andin seeding them or it directly into a medium as claimed in claim
 15. 36.A method for adapting an in vitro culture in a medium with serum, to aculture in a protein-free medium, characterized in that it consists inrecovering the cells and/or the tissue from the medium with serum, andin seeding them or it, stepwise, into a medium as claimed in claim 15,said medium having decreasing serum concentrations, respectively. 37.The method of adaptation as claimed in claim 36, characterized in thatsaid method of adaptation comprises the following four steps: step 1:75% medium with serum/25% serum-free medium+peptide extract, step 2: 50%medium with serum/50% serum-free medium+peptide extract, step 3: 25%medium with serum/75% serum-free medium+peptide extract, step 4: 100%serum-free medium+peptide extract.
 38. A method for adapting an in vitroculture in a medium with serum, to a culture in a protein-free medium,characterized in that said method comprises the following steps: step 1:carrying out the method as claimed in claim 32, step 2: recovering thecells and/or the tissues from the serum-free medium, step 3: seedingsaid cells and/or tissues directly into a protein-free medium.
 39. Amedium for culturing in vitro animal cells or tissues, which comprisesan animal protein-free medium and a peptide extract obtained bysuccessive fractionations of a plant starting material, wherein saidplant starting material consists of rapeseed.
 40. The medium forculturing in vitro animal cells or tissues according to claim 39,wherein said plant starting material consists of rapeseed cake.
 41. Themedium for culturing in vitro animal cells or tissues according to claim39, wherein said extract consists of at least 80% by mass of nitrogenousmaterial.
 42. The medium for culturing in vitro animal cells or tissuesaccording to claim 39, wherein said extract consists of at least 90% bymass of nitrogenous material.
 43. The medium for culturing in vitroanimal cells or tissues according to claim 41, wherein said nitrogenousmaterial consists of approximately 50% to approximately 60% of peptideshaving a molecular size of less than 500 daltons.
 44. The medium forculturing in vitro animal cells or tissues according to claim 41,wherein said nitrogenous material consists of approximately 20% toapproximately 30% of peptides having a molecular size of between 500 and1000 daltons.
 45. The medium for culturing in vitro animal cells ortissues according to claim 39, wherein said extract comprises between 20and 40 mol % of aspartic acid and of glutamic acid and/or of theirrespective amides.
 46. The medium for culturing in vitro animal cells ortissues according to claim 39, wherein said extract has the followingtotal amino acid composition: Amino acids Molar % Alanine 2-6 Arginine5-9 Aspartic acid + asparagine 10-14 Cysteine 0 Glutamic acid +Glutamine 15-19 Glycine  7-11 Histidine 1-5 Isoleucine 2-6 Leucine 5-9Lysine 2-6 Méthionine 0-3 Phenylalanine 1-5 Proline 3-7 Serine 5-9Threonine 5-9 Tryptophan not determined Tyrosine 1-5 Valine 5-9